Qhrd106
Acute Ischemic Stroke
Changzhou Qianhong Bio-pharma Co., Ltd.Phase 2Active
CCC
52/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 45/ 100
- Competitive Position
- 65/ 100
Competitive context
210 Active assets in the Acute Ischemic Stroke cohort.
View all 50 →
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →